Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma by Chakraborty, Sanjukta et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Involvement of TSC genes and differential expression of other 
members of the mTOR signaling pathway in oral squamous cell 
carcinoma
Sanjukta Chakraborty1, SM Azeem Mohiyuddin2, KS Gopinath2,3 and 
Arun Kumar*1
Address: 1Department of Molecular Reproduction Development and Genetics, Indian Institute of Science, Bangalore, India, 2RL Jalappa Hospital 
and Research Centre, Kolar, India and 3Bangalore Institute of Oncology, Bangalore, India
Email: Sanjukta Chakraborty - sanjuc8@gmail.com; SM Azeem Mohiyuddin - azeem_hn@hayoo.co.in; 
KS Gopinath - drgopinath@hotmail.com; Arun Kumar* - karun@mrdg.iisc.ernet.in
* Corresponding author    
Abstract
Background: Despite extensive research, the five-year survival rate of oral squamous cell carcinoma (OSCC) patients has not
improved. Effective treatment of OSCC requires the identification of molecular targets and signaling pathways to design
appropriate therapeutic strategies. Several genes from the mTOR signaling pathway are known to be dysregulated in a wide
spectrum of cancers. However, not much is known about the involvement of this pathway in tumorigenesis of OSCC. We
therefore investigated the role of the tumor suppressor genes, TSC1 and TSC2, and other members of this pathway in
tumorigenesis of OSCC.
Methods: Expression of genes at the RNA and protein levels was examined by semi-quantitative RT-PCR and western blot
analyses, respectively. Loss of heterozygosity was studied using matched blood and tumor DNA samples and microsatellite
markers from the TSC1, TSC2 and PTEN candidate regions. The effect of promoter methylation on TSC gene expression was
studied by treating cells with methyltransferase inhibitor 5-azacytidine. Methylation status of the TSC2 promoter in tissue
samples was examined by combined bisulfite restriction analysis (COBRA).
Results: The semi-quantitative RT-PCR analysis showed downregulation of TSC1, TSC2, EIF4EBP1 and PTEN, and upregulation
of PIK3C2A, AKT1, PDPK1, RHEB, FRAP1, RPS6KB1, EIF4E and RPS6 in tumors. A similar observation was made for AKT1 and
RPS6KB1 expression in tumors at the protein level. Investigation of the mechanism of downregulation of TSC genes identified
LOH in 36.96% and 39.13% of the tumors at the TSC1 and TSC2 loci, respectively. No mutation was found in TSC genes. A low
LOH rate of 13% was observed at the PTEN locus. Treatment of an OSCC cell line with the methyltransferase inhibitor 5-
azacytidine showed a significant increase in the expression of TSC genes, suggesting methylation of their promoters. However,
the 5-azacytidine treatment of non-OSCC HeLa cells showed a significant increase in the expression of the TSC2 gene only. In
order to confirm the results in patient tumor samples, the methylation status of the TSC2 gene promoter was examined by
COBRA. The results suggested promoter hypermethylation as an important mechanism for its downregulation. No correlation
was found between the presence or absence of LOH at the TSC1 and TSC2 loci in 50 primary tumors to their clinicopathological
variables such as age, sex, T classification, stage, grade, histology, tobacco habits and lymph node metastasis.
Conclusion: Our study suggests the involvement of TSC genes and other members of the mTOR signaling pathway in the
pathogenesis of OSCC. LOH and promoter methylation are two important mechanisms for downregulation of TSC genes. We
suggest that known inhibitors of this pathway could be evaluated for the treatment of OSCC.
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Background
Oral squamous cell carcinoma (OSCC) is the sixth most
common cancer in the world [1]. In India, it is the leading
cancer among males and the third most common malig-
nancy in females [1]. The five-year survival rate for OSCC
is the lowest among all major cancers [1]. The etiology of
this cancer is multifactorial, with important risk factors
being tobacco intake, alcohol consumption and human
papilloma virus (HPV).
A thorough understanding of the genetic and epigenetic
changes that result in the activation of signaling pathways
and provide the cells with a growth advantage during oral
tumorigenesis is essential for the development of novel
therapeutic strategies. Agents that can inhibit or reverse
these changes by targeting molecularly defined pathways
should receive increased attention as novel candidates for
oral cancer prevention and therapy [2,3]. The molecular
interplay between phosphoinositide-3-kinase, catalytic,
alpha polypeptide (PIK3CA) and FK506 binding protein
12-rapamycin associated protein 1 (FRAP1) of the mTOR
(mammalian target of rapamycin) signaling pathway in
the control of cell growth and proliferation has been the
subject of much interest among cell biologists [4].
Tuberin, encoded by the tumor suppressor gene tuberous
sclerosis 2 (TSC2), and its interacting partner hamartin,
encoded by another tumor suppressor gene tuberous scle-
rosis 1 (TSC1), have been placed as a complex in the
mTOR signaling pathway and negatively regulate the
pathway to inhibit mTOR mediated downstream signal-
ing [4]. Several components of the mTOR signaling path-
way are known to be dysregulated in a wide spectrum of
human cancers [5]. Although some components
(PIK3C2A, AKT1, PTEN, RPS6 and EIF4E) of this pathway
have been implicated in OSCC [6-9], a comprehensive
analysis is lacking. Further, very little is known about the
roles of TSC tumor suppressor genes in tumorigenesis of
OSCC [10]. The main aim of this study was to assess the
role of TSC genes and other members of this pathway in
the tumorigenesis of OSCC. The results of our study are
presented here.
Methods
Sample collection
A total of 52 OSCC (oral cancer) samples were ascertained
at Bangalore Institute of Oncology, Bangalore. All tumor
samples were from the tongue and cheek areas of the
mouth. Lesions were situated at the anterior 2/3 of the
tongue over the lateral borders, a common site in Indian
patients. This study was performed with informed written
consent from the patients and approval from the ethics
committees of the Bangalore Institute of Oncology and
Indian Institute of Science. The specimens were obtained
as biopsy or surgical samples from oral cancerous lesions
and adjacent normal mucosa (taken from the farthest
margin of the surgical resection). The patients had not
been treated at the time of biopsy/surgery. The clinico-
pathological data for 52 patients is given in Table 1.
Tumors were classified according to TNM (Tumor, Node
and Metastasis) criteria [11]. Peripheral blood samples
were also collected in EDTA-Vacutainer (Beckton-Dickin-
son, Franklin Lakes, NJ) tubes from 52 patients.
Cell culture
Three oral cancer cell lines (SCC 131, SCC 104 and KB)
and four other cell lines (HeLa, HepG2, A549 and HEK-
293T) were used. SCC 131 and SCC 104 cell lines were a
kind gift from Dr. Susanne M. Gollin (University of Pitts-
burgh, Pittsburgh, PA). Cell lines were maintained either
in Minimum Essential Medium with Earle's salt and l-
glutamine or in Dulbecco's modified Eagle's medium
(Sigma-Aldrich, St. Louis, MO).
Genomic DNA isolation
Genomic DNA was isolated from peripheral blood and
tumor samples using a DNA isolation kit (Roche Diagnos-
tics™, Mannheim, Germany).
Semi-quantitative RT-PCR
Total RNA was isolated from 16 paired normal and tumor
samples using the TRI REAGENT™ (Sigma-Aldrich, St.
Louis, MO). cDNA was synthesized from 1 μg total RNA
from each sample using random hexamers and the Rever-
taid™ H Minus First Strand cDNA Synthesis Kit (MBI Fer-
mentas, Burlington, ON, Canada). For RT-PCR, forward
Table 1: Clinicopathological features of patients included in the 
study.
Characteristics No. of patients (n = 52)
Median age/range 50 yrs/32–70 yrs
Gender
Males 14 (26.92%)
Females 38 (73.08%)
Tumor classification
T1 2 (3.85%)
T2 8 (15.38%)
T3 14 (26.92%)
T4 26 (50%)
Epithelial dysplasia 2 (3.85%)
Tobacco use
Tobacco positive 50 (96.15%)
Tobacco negative 2 (3.85%)
Treatment
Surgery 50 (96.15%)
No surgery 2 (3.85%)
Radiotherapy 47 (90.38%)
Chemotherapy 5 (9.62%)
Lymph node
Positive 32 (61.54%)
Negative 16 (30.77%)
Unknown 4 (7.69%)BMC Cancer 2008, 8:163 http://www.biomedcentral.com/1471-2407/8/163
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and reverse primers were selected from two different
exons of genes to rule out the possibility of amplification
of contaminating genomic DNA. Primer sequences and
PCR conditions are available from the authors upon
request. For each gene, the PCR protocol was optimized in
order to get the amplification in a linear phase. Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was
amplified as a normalizing control. Images of RT-PCR
ethidium bromide stained agarose gels were acquired with
a Kodak CCD camera and quantification of the bands was
performed by densitometric analysis using the Kodak Dig-
ital Science Image Station Imaging Software version 3.6.1.
Band intensity was expressed as relative absorbance units.
Data was expressed in arbitrary units (relative expression)
as a ratio of normal/GAPDH and tumor/GAPDH and plot-
ted using the GraphPad Prism software version 4.00
(GraphPad Prism Software, San Diego, CA). The signifi-
cance of difference in mRNA levels between normal and
tumor samples for a gene was assessed by Student's t-test
and the results are expressed as mean ± SEM [12]. A prob-
ability value of p < 0.05 was assumed to be significant.
PCR amplification for each gene was repeated once. A
gene was considered to be upregulated when its mean
expression value across 16 tumor samples was signifi-
cantly higher than the mean expression value across 16
normal tissue samples and vice versa [13]. We defined the
cutoff value for determining the upregulation or downreg-
ulation of a gene in a tumor sample as ≥ 1.8 fold differ-
ence in its expression between normal and tumor samples
as described by Arora et al. [3] for differentially expressed
genes in oral squamous cell carcinoma.
Mutation analysis
Mutation screening of the entire coding regions of TSC
genes was carried out using PCR-SSCP [14] and DNA
sequencing techniques.
LOH analysis at TSC1, TSC2 and PTEN loci
For LOH studies, matched normal and tumor DNA sam-
ples from 50 patients were genotyped using following
microsatellite markers: D9S179, D9S1830 and D9S915
for the TSC1 locus; D16S3024, D16S3395 and D16S475
for the TSC2 locus; and D10S215, D10S1765 and
D10S541 for the PTEN locus. Microsatellite analysis was
performed as described in Kumar et al. [15]. LOH was
scored if there was a complete loss of one of the two het-
erozygous alleles in tumor DNA or a decrease of 50%
intensity of one of the two alleles in tumor DNA as com-
pared to the corresponding peripheral blood DNA (allelic
imbalance).
Antibodies and western blot analysis
Rabbit polyclonal antibodies generated against amino
acids 488–1016 of TSC1 and amino acids 155–541 of
TSC2 were raised in our laboratory. Mouse monoclonal
anti-β-actin antibody was purchased from Sigma-Aldrich
(St. Louis, MO). Rabbit polyclonal anti-Akt 1/2, anti-p-
Akt 1/2/3 (Thr 308) and anti-p-p70S6K1 (Thr 389) anti-
bodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Rabbit polyclonal anti-p70S6K1 anti-
body was obtained as a kind gift from Dr. I. Juhan-Vague
(Marseille, Cedex, France).
For western blot analysis, whole cell lysates were prepared
from matched normal and tumor samples as well as cell
lines using a standard procedure. Equal amounts of pro-
tein (~100 μg/lane) from tumor, normal oral tissue or dif-
ferent cancer cell lines were resolved by SDS-
polyacrylamide gel electrophoresis and transferred onto a
PVDF membrane. Primary antibody was detected with
either HRP-conjugated goat anti-rabbit or goat anti-
mouse secondary antibodies (Bangalore Genei™, India).
Immunoreactive bands were visualized using the Western
Lightning Chemiluminescence Reagent kit (PerkinElmer
Life Sciences, Boston, MA) and X-ray films. β-actin was
used to see equal protein loading.
5-azacytidine treatment of cell lines
SCC 131 and HeLa cells were seeded at a density of 1 × 106
cells/90 mm dish. After 24 hr, freshly prepared 5-azacyti-
dine (Sigma-Aldrich, St. Louis, MO) was added into the
dish to a final concentration of 10 μM. Total RNA was iso-
lated after 2 and 5 days from the start of the treatment.
Untreated cells were used as controls. Semi-quantitative
RT-PCR was used to assess the expression of TSC1 and
TSC2. GAPDH was used as a normalizing control.
Combined bisulfite restriction analysis
Methylation status of the TSC2 gene promoter was exam-
ined using combined bisulfite restriction analysis
(COBRA) as described by Xiong and Laird [16]. Sodium
bisulfite treated DNA was used in PCR amplification
using primers designed for the bisulfite treated DNA.
Primers were designed using the MethPrimer program
[17]. Promoter region of the TSC2 gene is reported by
Kobayashi et al. [18]. Sodium bisulfite treated DNA was
amplified with following TSC2  promoter primers: F-
5'gggattttagtttgtagtttttattt-3' and R-5'-ccataact-
taaaactaaaaaatact-3'. Primers were designed to exclude
binding to any CpG dinucleotide to ensure amplification
of both methylated and unmethylated forms of DNA.
PCR conditions for primers were as follows: an initial
denaturation at 95°C for 3 min was followed by 35 cycles
of 94°C for 30 sec, 60°C for 45 sec and 68°C for 45 sec
with a final extension at 68°C for 5 min. TSC2 primer set
generated a 571 bp amplicon. A second PCR was carried
out using the product of the first amplification as a tem-
plate to get enough DNA for COBRA. Approximately 500–
600 ng of pooled and gel purified PCR product was
digested with Aci I at 37°C for 6 hr. Digests were resolvedBMC Cancer 2008, 8:163 http://www.biomedcentral.com/1471-2407/8/163
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in a 2.5% agarose gel and visualized by ethidium bromide
staining. There are 18 Aci I sites and 65 CpGs in the TSC2
promoter. The restriction enzyme Aci I recognizes the
sequence 5'-GCGG-3'. The cleavage of this sequence will
occur only when the C residue in the recognition
sequence is methylated. Promoter of TSC1  has been
reported by Ali et al. [19]. Primers were also designed for
the  TSC1  promoter. However, despite repeated efforts
using DNA polymerases from several vendors, we were
not successful in amplifying the TSC1  promoter after
bisulfite treatment.
Results and discussion
Downregulation of TSC genes
Expression levels of TSC genes were studied by semi-quan-
titative RT-PCR analysis in a panel of 16 matched normal
and tumor samples. The mean expression level of TSC1
was significantly lower (1.31 ± 0.18 in normal vs. 0.79 ±
0.11 in tumor, p = 0.0208) in tumor samples (Figure 1a).
The mean expression level of TSC2 was also significantly
lower (1.56 ± 0.15 in normal vs. 0.88 ± 0.12 in tumor, p
= 0.0013) in tumor samples (Figure 1a), suggesting the
involvement of these genes in the etiology of oral cancer.
Expression of TSC genes in oral tumor samples and cell lines Figure 1
Expression of TSC genes in oral tumor samples and cell lines. a) Semi-quantitative RT-PCR analysis of TSC genes in 16 
matched normal and tumor samples. Note, downregulation of both genes in tumor samples. Each square or triangle corre-
sponds to data from one sample. Horizontal lines represent mean values of mRNA expression across normal or tumor sam-
ples. b) Western blot analysis of TSC1 and TSC2 in eight matched normal and tumor tissues. TSC1 and TSC2 show no 
expression or downregulation in tumor samples. c) Western blot analysis of TSC1 and TSC2 in three oral cancer (KB, SCC 
104 and SCC 131), lung carcinoma (A549), embryonic kidney (HEK-293T), cervical carcinoma (HeLa) and hepatic carcinoma 
(HepG2) cell lines. Note, the expression of TSC2 is not detectable in the oral cancer cell line SCC 131.
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TSC1 and TSC2 were also downregulated in eight
matched normal and tumor samples at the protein level
(Figure 1b). We wanted further to determine the expres-
sion of both the TSC genes in cell lines. Interestingly,
TSC2 did not show a detectable level of expression in an
oral cancer cell line SCC 131, whereas it was expressed in
two other oral cancer cell lines KB and SCC 104 as well as
in A549, HEK-293T, HeLa and HepG2 at the protein level
(Figure 1c). However, the TSC2 expression in KB was
lower than in other cell lines (Figure 1c). TSC1 was
expressed in all the cell lines, albeit at different levels (Fig-
ure 1c).
Mechanisms of downregulation of TSC genes
We then sought to determine the mechanism of downreg-
ulation of TSC genes in tumor samples. Given the fact that
both are tumor suppressors, we hypothesized that their
downregulation could be due to inactivating somatic
mutations, LOH and/or promoter methylation in tumors.
Mutation analysis of the entire coding regions of both the
TSC genes did not detect any mutation in a panel of 25
tumor samples. However, four normal population
sequence variants (c.965T>C/p.M322T, c.IVS10+51T>A,
c.IVS10+27C>G and c.1335A>G/p.E445E) were identified
in  TSC1. Three normal population sequence variants
(c.1578C>T/p.S526S, c.IVS14-14C>T and c.2580T>C/
p.F860F) were detected in TSC2. Interestingly, our analy-
sis of matched peripheral blood and tumor DNA samples
from 50 patients showed LOH at both the TSC loci (Figure
2). Of 50 patients, 46/50 patients were constitutionally
heterozygous for one or more markers at each of the two
TSC loci (Figure 2b). At the TSC1 locus, 17/46 (36.96%)
tumors showed an allelic loss for one or more markers.
The frequency of LOH at each of the markers analyzed was
as follows: 3/29 (10.34%) informative cases for D9S179,
8/45 (17.78%) informative cases for D9S1830 and 12/44
(27.27%) informative cases for D9S915 (Figure 2b). At
the TSC2 locus, 18/46 (39.13%) informative cases
showed an allelic loss for one or more markers. LOH was
found in 5/25 (20%) informative cases for D16S3024, 8/
38 (21.05%) informative cases for D16S3395 and 11/37
(29.73%) informative cases for D16S475 (Figure 2b).
Nine patients (9/46; 19.57%) had LOH at both the TSC
loci (Figure 2b). Microsatellite instability (MI) was found
LOH at TSC loci in 50 matched normal and tumor samples Figure 2
LOH at TSC loci in 50 matched normal and tumor samples. a) Representative gel pictures showing LOH for markers 
from the TSC1 and TSC2 candidate regions. B and T denote constitutive blood and tumor DNA respectively. Arrows indicate 
loss or allelic imbalance of the corresponding allele in tumor DNA. b) LOH analysis of 50 matched samples at both the TSC 
loci. Approximate locations of microsatellite markers with respect to TSC genes are shown on the left. Tumors are grouped 
according to their T classification (T1–T4). Numbers represent patient numbers. Abbreviations: NI, non-informative; IN, 
informative; LOH, loss of heterozygosity; and MI, microsatellite instability.
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in patient 40 at D9S179 and patient 53 at D16S3395 and
D16S475 (Figure 2b). No LOH was found in two ED (epi-
thelial dysplasia) samples at either of the two TSC loci
(data not shown).
In spite of the exciting link of TSC genes with the mTOR
signaling pathway so widely linked with the onset and
progression of tumorigenesis, only few studies have inves-
tigated the role of TSC genes in sporadic cancers. Hebert et
al. [10] have detected a few mutations in both TSC genes
in head and neck tumors from the U.S. patients and SCC
cell lines. Although reduced expression of tuberin was
found in sporadic astrocytomas, no intragenic mutations
were detected in either TSC gene [20]. LOH was seen in
astrocytomas, ependymomas, gangliogliomas, glioblast-
oma multiforme, oligodendrogliomas and pilocytic astro-
cytomas at both the TSC loci [20]. Parry et al. [21] did not
detect any intragenic somatic mutation in TSC genes in
sporadic renal cell carcinomas, although LOH was found
at both the TSC loci. Somatic mutations in TSC1 have
been identified in bladder tumors [22]. LOH at the TSC
loci has been reported in several other tumor types: lung
adenocarcinoma, gall bladder cancer, nasopharyngeal
cancer, papillary breast tumors and ovarian serous adeno-
carcinoma [22,23]. The present study is the first report to
describe LOH at both the TSC loci in OSCC. Further, the
expression of the TSC1 and TSC2 genes was found to be
significantly downregulated in a majority of oral tumors,
both at the RNA and protein levels (Figure 1, Table 2).
These results suggest that both the TSC genes act as tumor
suppressors in tumorigenesis of OSCC. Our results are in
agreement with the studies carried out on both TSC1 and
TSC2 in breast cancer and on TSC2 in pancreatic cancer,
which have recorded reduced and aberrant expression of
these genes [24,25]. Although LOH and somatic muta-
tions are important mechanisms for downregulation of
tumor suppressor genes, there are examples, where LOH
without somatic mutations has been found to be respon-
sible for the downregulation of these genes. For example,
LOH without somatic mutations in TSC genes was found
to be an important mechanism for downregulation of
these genes in sporadic glial and glioneuronal tumors
[20]. Promoter methylation and LOH without somatic
mutations are known to downregulate ATM  and  FHIT
genes in breast cancer [26,27]. It is reasonable to assume
that the LOH due to deletion of one of the two alleles or
due to loss of an entire chromosome with TSC1 or TSC2
gene in tumors will leave only one allele, resulting in the
downregulation of these genes.
Aberrant hypermethylation of promoter CPG islands has
been found to be an important alternative mechanism to
intragenic mutations for the inactivation of tumor sup-
pressor genes [28]. Since we did not find any somatic
mutation in TSC genes in oral tumors, we therefore
ascribed the downregulation of TSC genes in oral cancer
to an epigenetic alteration, resulting in the methylation of
TSC1 and TSC2 promoters. To investigate if the downreg-
ulation of TSC genes in tumors is due to their promoters
being methylated, we selected the oral cancer cell line SCC
131, which did not show expression of TSC2 and a low
level of expression of TSC1 (Figure 1c), and treated it with
methyltransferase inhibitor 5-azacytidine. RT-PCR data
showed a significant increase in the expression of both the
TSC genes in this cell line following the treatment (Figure
3). HeLa cells also showed a significant increase in the
expression of TSC2 after 5-azacytidine treatment (Figure
3b). However, no significant difference was observed in
the expression of TSC1 in HeLa cells following the drug
treatment for 2 and 5 days (Figure 3b). No change in the
expression of both the genes was seen in both cell lines
grown for 2 and 5 days without the drug treatment (Figure
3b).
Table 2: Clinicopathological characteristics, LOH and gene expression variation in folds* for 16 tumor samples.
Sample 
(Patient) 
no.
Age 
(yrs)/
Sex
Tumor 
classification
Metastasis Tobacco 
use
LOH@ 
TSC1
LOH@ 
TSC2
TSC1 
(D)
TSC2
(D)
AKT1
(U)
PIK3C2A
(U)
PDPK1
(U)
RHEB
(U)
FRAP1
(U)
RPS6KB1
(U)
RPS6
(U)
EIF4E
(U)
EIF4EBP1
(D)
PTEN
(D)
54 40 M T4N1M0 N/A Yes - - 1.39 2.04 2.04 2.34 0.77 2.29 1.82 2.25 3.40 2.23 3.12 1.70
39 55 F T4N1M0 Yes Yes - - 1.77 1.95 4.04 2.47 2.33 1.92 2.68 3.34 2.67 3.01 0.98 1.44
19 48 F T4N2bM0 No Yes - - 1.93 3.57 3.29 1.63 1.57 2.12 2.21 2.93 2.01 2.07 1.45 2.04
15 55 F T3N1M0 No Yes - - 2.63 2.03 4.68 3.23 1.81 0.76 1.76 1.48 2.83 1.31 3.03 2.35
20 50 F T4N1M0 Yes Yes - - 1.98 2.03 1.46 1.65 0.65 0.85 0.92 1.34 1.50 1.98 3.02 1.87
85 0  F T 3N1M0 No Yes - - 1.15 1.37 1.57 0.95 1.39 1.73 0.44 0.61 0.64 1.54 4.27 3.67
11 60 F T4N1Mx Yes Yes - - 0.31 0.69 1.80 1.69 1.03 2.54 3.76 1.94 0.69 1.17 0.96 2.36
40 50 F T2N1M0 Yes Yes + - 2.33 1.48 1.75 2.16 1.90 2.22 2.82 6.25 1.83 4.22 2.06 1.60
50 40 M T4N2bM0 Yes Yes - - 1.20 2.98 1.34 0.58 1.43 1.22 1.25 2.45 2.69 1.50 3.67 1.35
52 70 M ED N/A No - - 2.35 1.82 2.69 2.64 1.50 2.23 5.78 1.80 1.76 3.74 1.69 2.23
32 35 M T4N0Mx No Yes - - 1.58 3.03 2.04 0.90 1.15 0.80 1.48 1.67 1.89 1.60 2.24 1.18
53 38 F T2N0M0 No Yes + - 7.92 1.51 3.68 2.88 2.59 2.78 1.19 2.32 1.21 2.13 2.77 1.99
55 40 F T4N1M0 Yes Yes + - 1.35 1.81 2.27 2.99 1.53 1.70 12.4 1.37 4.47 2.67 1.77 1.46
57 62 F T1N0M0 Yes Yes - - 1.40 2.39 2.26 4.50 8.26 2.95 2.24 5.05 1.80 2.32 2.17 0.50
59 70 F T4N2bM0 Yes Yes - + 2.38 1.30 1.48 2.80 1.92 1.67 1.38 0.67 1.66 1.70 5.07 1.23
60 40 F T4aN1Mx Yes Yes - - 1.37 1.80 0.87 2.28 1.49 1.98 1.05 1.04 1.99 1.88 0.60 1.30
* We defined the cutoff value for determining the upregulation or downregulation of a gene in a tumor sample as ≥ 1.8 fold difference in its expression between normal and tumor samples [3]. With this criterion, TSC1, TSC2, EIF4EBP1 and PTEN 
genes showed downregulation in 7/16, 11/16, 10/16 and 7/16 tumor samples, respectively. Whereas AKT1, PIK3C2A, PDPK1, RHEB, FRAP1, RPS6KB1, RPS6 and EIF4E showed upregulation in 10/16, 10/16, 6/16, 9/16, 8/16, 9/16, 10/16 and 10/16 
tumor samples, respectively.
Abbreviations: TNM, Tumor, Node, Metastasis; and ED, Epithelial dysplasia.
'Yes' in tobacco use refers to addiction to tobacco, bidi and cigarettes for at least 15–20 years. '+' denotes LOH found; '-' denotes no LOH; N/A, not applicable;
(D)denotes downregulation of gene expression and (U)denotes upregulation of gene expression across 16 tumor samples.BMC Cancer 2008, 8:163 http://www.biomedcentral.com/1471-2407/8/163
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In order to see if the downregulation of TSC genes is due
to their promoters being methylated in tumors from the
patients, we examined the methylation status of the pro-
moters of both the TSC genes in a panel of 16 oral tumors,
three normal oral tissues, two peripheral blood DNA sam-
ples from normal individuals, and two cell lines HeLa and
SCC 131 by COBRA. Our repeated efforts to amplify the
TSC1  promoter using different Taq  DNA polymerases
failed. We believe that this could be due to the nature of
the sodium bisulfite treated DNA. However, we were able
to successfully amplify the 571 bp long TSC2 promoter
region. As can be seen from the Figure 4a, a 571 bp PCR
product from all the tumors and both cell lines showed
digestion, whereas PCR products from peripheral blood
samples from two normal individuals and three normal
oral tissues did not show digestion. Digested bands of var-
ying sizes and intensities were seen in different tumor
samples and both cell lines, in addition to a prominent
digested band of ~175 bp and the uncut band of 571 bp
(Figure 4a). In order to see if the digestion by Aci I was
specific, we treated the PCR products with the restriction
enzyme buffer only. The absence of any digestion sug-
gested that the Aci I digestion of the samples was specific
(data not shown). Sequence analysis of the PCR products
from sodium bisulfite treated normal and tumor DNA
showed that the treatment was specific (Figure 4b).
The variation in the degree of digestion by Aci I in differ-
ent tumor samples might be accounted for by the fact that
all surgical samples are likely to contain a heterogenous
Expression of TSC genes in cancer cell lines following treatment with 5-azacytidine for 2 (2 d) and 5 (5 d) days Figure 3
Expression of TSC genes in cancer cell lines following treatment with 5-azacytidine for 2 (2 d) and 5 (5 d) days. 
a) Representative RT-PCR gel pictures showing restoration or increase in the expression of TSC genes. b) Graphical represen-
tation of expression levels of TSC1 and TSC2 following the drug treatment. Expressions of these genes in untreated SCC 131 
and HeLa cells at day 0, 2 and 5 were used as controls. '-' indicates no 5-azacytidine treatment and '+' indicates treatment with 
5-azacytidine. Graphs represent mean ± SEM of two separate experiments. * indicates significant difference at p < 0.05. 
Although the expression of TSC1 was increased in HeLa cells following the drug treatment, the relative expression levels of 
treated and untreated cells were not significantly different from each other. The expression of TSC2 was significantly increased 
in both cell lines following the drug treatment.
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mix of normal and tumor cells as microdissection was not
performed on tumor samples and also considerable heter-
ogeneity of methylation might exist among tumor sam-
ples. An MSP (methylation-specific PCR) assay could not
be designed in this study because the relevant methylated
region was limited. Taken together, our 5-azacytidine and
COBRA data suggested that TSC genes are targets of epige-
netic inactivation in oral cancer (Figures 3 and 4).
Aberrant expression of genes from the mTOR signaling 
pathway
Since TSC1 and TSC2 are important regulators of this
pathway and showed downregulation, we hypothesized
that other key players of this pathway might be also dys-
regulated in oral cancer. To this end, the expression pat-
tern of other major regulators of this pathway [v-akt
murine thymoma viral oncogene homolog 1 (AKT1);
phosphoinositide-3-kinase, class 2, alpha polypeptide
(PIK3C2A); 3-phosphoinositide dependent protein
kinase-1 (PDPK1); Ras homolog enriched in brain
(RHEB); FK506 binding protein 12-rapamycin associated
protein 1 (FRAP1); ribosomal protein S6 kinase, 70 kDa,
polypeptide 1 (RPS6KB1); ribosomal protein S6 (RPS6);
eukaryotic translation initiation factor 4E (EIF4E); eukary-
otic translation initiation factor 4E binding protein 1
(EIF4EBP1); phosphatase and tensin homolog, mutated
in multiple advanced cancers 1 (PTEN); tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activa-
tion protein, beta polypeptide (YWHAB); and insulin
receptor substrate 1 (IRS1)] was investigated in the same
panel of 16 matched normal and tumor tissues using
semi-quantitative RT-PCR analysis. Mean expression lev-
els of following genes showed significant upregulation in
tumor samples: AKT1 (0.61 ± 0.08 in normal vs. 1.30 ±
0.16 in tumor, p = 0.0008), PIK3C2A (0.74 ± 0.12 in nor-
mal vs. 1.39 ± 0.17 in tumor, p = 0.0038), PDPK1 (0.79 ±
0.09 in normal vs. 1.19 ± 0.09 in tumor, p = 0.0041),
RHEB (0.68 ± 0.09 in normal vs. 1.13 ± 0.13 in tumor, p
= 0.0088), FRAP1 (0.54 ± 0.09 in normal vs. 0.91 ± 0.10
in tumor, p = 0.0095), RPS6KB1 (0.53 ± 0.08 in normal
vs. 0.97 ± 0.12 in tumor, p = 0.0048), RPS6 (0.99 ± 0.18
in normal vs. 1.64 ± 0.19 in tumor, p = 0.02) and EIF4E
(0.72 ± 0.08 in normal vs. 1.45 ± 0.17 in tumor, p =
0.0004) (Figure 5a). Whereas mean expression levels of
EIF4EBP1 (1.23 ± 0.14 in normal vs 0.56 ± 0.06 in tumor,
p = 0.0001) and PTEN (1.27 ± 0.17 in normal vs. 0.73 ±
Analysis of the methylation status of the TSC2 promoter by COBRA and bisulfite sequencing Figure 4
Analysis of the methylation status of the TSC2 promoter by COBRA and bisulfite sequencing. a) Bisulfite treated 
DNA samples from 16 oral tumors, three normal oral tissues, peripheral blood samples from two normal individuals and two 
cell lines were analyzed by COBRA. Normal and tumor samples are marked as N and T, respectively. Numbers correspond to 
patient numbers. Note, the undigested 571 bp fragment and a major digested fragment of ~175 bp in all tumors and cell lines. 
CB DNA1 and CB DNA 2 are peripheral blood DNA samples from two unrelated normal individuals. b) Representative 
bisulfite sequencing chromatograms of the promoter region from normal and tumor samples. The underlined region denotes 
the Aci I site which is lost in the normal tissue from patient 55 and retained in the tumor from patient 59 because of methyla-
tion at the C residue at this site.BMC Cancer 2008, 8:163 http://www.biomedcentral.com/1471-2407/8/163
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Expression of other members of the mTOR signaling pathway in oral tumors Figure 5
Expression of other members of the mTOR signaling pathway in oral tumors. a) mRNA expression of 10 genes in 
16 matched normal and tumor samples. Horizontal lines represent mean values of mRNA expression across normal or tumor 
samples. b) Western blot analysis of matched normal (N) and tumor (T) samples from eight patients. Numbers represent 
patient numbers. Blots were probed with antibodies for anti-AKT, anti-p-AKT (Thr308), anti-p70S6K1 and anti-p-70S6K1 
(Thr389).
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0.08 in tumor, p = 0.0075) showed significant downregu-
lation in tumor samples (Figure 5a). Two other genes of
this pathway, YWHAB (0.81 ± 0.89 in normal vs. 1.06 ±
0.12 in tumor, p = 0.1153) and IRS1 (0.94 ± 0.10 in nor-
mal vs. 1.19 ± 0.12 in tumor, p = 0.1118) did not show
any significant difference in expression levels between
normal and tumor samples (data not shown). We then
analyzed the expression pattern of a few genes (AKT1 and
RPS6KB1) at the protein level using eight matched normal
and tumor tissues. The level of total AKT1 was upregulated
in 2/8 tumor samples only (Figure 5b). However, p-AKT1
(Thr308) showed upregulation in 7/8 samples (Figure
5b). p70S6K1 (RPS6KB1) and p-p70S6K1 (Thr389) were
both upregulated in 8/8 and 6/8 tumor samples, respec-
tively (Figure 5b). Increase in the phosphorylated forms
of both AKT1 and its downstream effector p70S6K1 sug-
gested an increase in their kinase activity, indicating a con-
stitutive activation of this pathway in oral cancer.
Upregulation of PIK3C2A  has been reported in several
cancers such as cervical, colon, breast, liver, stomach and
lung cancers [29]. Expression of this gene has been inves-
tigated in oral tongue carcinoma, and head and neck can-
cer cell lines where the mean expression level in tumor
samples was found to be significantly higher than in nor-
mal samples [7]. Our results have also shown that
PIK3C2A is upregulated in 10/16 oral tumors (Figure 5a,
Table 2).
AKT1 (AKT) is a downstream effecter of PIK3C2A (PI3K).
It has emerged as a central player controlling several signal
transduction pathways that are activated in response to
growth factors or insulin. Activation of AKT1 has been
shown to be a frequent event in breast, colorectal, ovarian,
pancreatic, and head and neck cancers [30]. One of the
best characterized regulators of the mTOR signaling path-
way is PTEN. The lipid phosphatase activity of PTEN acts
as a negative regulator for PIK3C2A induced signaling as
it dephosphorylates PIP3 [31]. PIP3 is a potent second
messenger that recruits certain kinases to the plasma
membrane including the Protein kinase B/Akt family of
kinases and PDPK1. On membrane localization, AKT1 is
activated in part through phosphorylation by PDPK1 and
elicits several downstream cellular functions. Genetic
inactivation of PTEN leads to constitutive activation of the
mTOR pathway [32]. Our study has shown that AKT1 and
PDPK1  show upregulation in 10/16 and 6/16 tumors
respectively (Figure 5a, Table 2). PTEN on the other hand
showed downregulation in 7/16 tumors (Figure 5a, Table
2). Mavros et al. [33] identified a low LOH rate of 12% in
50 samples of OSCC. They however did not find any
mutation in the coding region of PTEN and concluded
that the PTEN gene alterations do not play a key role in
tumorigenesis of oral squamous cell cancers. We have also
found a low LOH rate of 13% (6/46 informative cases) at
the PTEN locus in the same panel of 50 paired blood and
tumor DNA samples (data not shown). The frequency of
LOH was 4.5% (2/44 informative cases) and 10% (3/30
informative cases) at D10S1765 and D10S541 respec-
tively (data not shown). It is possible that the downregu-
lation of this gene in oral tumors examined in this study
is due to inactivating somatic mutations or its promoter
methylation. However, these possibilities need to be
investigated in the future.
FRAP1 has a central role in controlling cell cycle progres-
sion and cell growth. It has emerged as a major cancer
therapeutic target [34]. FRAP1 exerts its effect by phospho-
rylating EIF4EBP1 (4E-BP1) which binds to and inacti-
vates EIF4E, thus inhibiting 5'-cap-dependent mRNA
translation. Phosphorylation of EIF4EBP1 releases EIF4E
and allows initiation of translation. Regulation of EIF4E
mediated translation is an important target for therapeutic
intervention in light of the fact that EIF4E has been shown
to be overexpressed in several cancers and that overexpres-
sion can cause malignant transformation of rodent fibrob-
lasts [35]. In our study, EIF4EBP1  showed
downregulation in 10/16 tumors (Figure 5a, Table 2).
Upregulation of EIF4E in 10/16 tumors (Figure 5a, Table
2) potentiates its role in the increase of translation leading
to overall cell growth and proliferation. FRAP1 also regu-
lates translation via phosphorylation of a serine/threo-
nine kinase p70S6K1 (RPS6KB1). Upon phosphorylation,
p70S6K1 promotes translation of mRNAs containing a 5'
terminal oligopyrimidine (5' TOP) by phosphorylating
the ribosomal subunit S6. Since ribosomal proteins and
translation elongation factors are encoded by 5' TOP
mRNAs, signaling along the p70S6K1 pathway promotes
ribosome biogenesis and overall protein biosynthetic
capacity [4]. Our study provides the evidence that FRAP1
is upregulated in 8/16 tumors, as also are RPS6KB1 (9/16)
and RPS6 (10/16) (Figure 5a, Table 2). Our western blot
results also indicated that the AKT1/RPS6KB1 pathway is
active in oral tumors, as phosphorylated forms of both
proteins show increased levels in tumor samples (Figure
5b).
A novel positive regulator of FRAP1 is the small GTPase
RHEB [4]. Tuberin/hamartin complex acts as a negative
regulator of this pathway by C-terminal GAP activity of
tuberin towards RHEB. When stimulated by growth fac-
tors, AKT1 relieves this inhibition by phosphorylation of
tuberin, which dissociates the tuberin/hamartin complex
[4]. Phosphorylated tuberin binds to the 14-3-3 family of
proteins which control various cellular functions [4]. We
found upregulation of RHEB in 9/16 tumors (Figure 5a,
Table 2), whereas we did not find any significant differ-
ence in the expressions of the tuberin interacting protein
YWHAB (14-3-3β) and IRS1 across the samples analyzed
(data not shown). Interestingly, 14-3-3zeta, anotherBMC Cancer 2008, 8:163 http://www.biomedcentral.com/1471-2407/8/163
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tuberin interacting protein [36], was recently found to be
upregulated in OSCC [37]. Further, the expression of 14-
3-3sigma, which also interacts with tuberin [36], was
reduced or absent in OSCC [38]. This suggested that dif-
ferent isoforms of the 14-3-3 family behave differently in
OSCC.
Clinicopathological characteristics of patients with LOH 
at TSC1 and TSC2 loci
We correlated the presence or absence of LOH at the TSC1
and TSC2 loci in 50 primary tumors to their clinicopatho-
logical variables such as age, sex, T classification, stage,
grade, histology, tobacco habits and lymph node metasta-
sis. Fisher's exact test (two-sided) was carried out and a p
< 0.05 was considered to be significant. Using the above
criteria, none of the parameters examined demonstrated a
significant correlation with LOH at either of the TSC loci
(data not shown).
Conclusion
Collectively, the detection of LOH in a proportion of
OSCC samples coupled with reduced gene expression
both at the RNA and protein levels indicates a loss of func-
tion of TSC genes, implicating their role as tumor suppres-
sors in oral cancer for the first time. Loss of function of
these genes may thus contribute to the constitutive activa-
tion of the mTOR signaling pathway leading to overall cell
growth and proliferation. Our studies have also shown for
the first time that several key members of this pathway
show aberrant expression in oral cancer and can provide
useful therapeutic targets. Several inhibitors of this path-
way, such as rapamycin and its derivatives which inhibit
mTOR (FRAP1) and the PI3K (PIK3C2A) inhibitor wort-
mannin, are in fact now being actively evaluated in clini-
cal trials for other cancers [31,34]. Further, rapamycin and
its derivative CCI-779 have been shown to reduce OSCC
tumor size in nude mice [8,39]. Thus, these inhibitors
could also be evaluated for the treatment of oral cancer.
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